This article is more than 5 years old. Information may no longer be current.

Eyenovia seeks $35 million IPO

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Eyenovia has filed an initial public offering to raise money to advance its micro-dosing technology, according to paperwork filed with the Securities and Exchange Commission.

The emerging company looks to raise $35 million with the offering, and its proposed Nasdaq Capital Market symbol is “EYEN.”

Eyenovia’s topical piezo-print micro-therapeutic approach to dosing, which delivers an 8-µL electronic micro-dose ejection of phenylephrine, has shown positive results in a recent phase 2 study compared with a 32-µL dose.